Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more
Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more
By | Little Medicine Monster Global ADC Pipeline Status As of December 6, 2023, a total of 1166 ADC pipelines have been developed globally, with 524 pipelines under research and 16 approved drugs (including two TDM-1 biosimilars). The abandonment rate of pipelines is as high as 54% (1166-524-16/1166). Among the 524 pipelines under research, over … Read more
Focused and dedicated, stepping onto the international stage Written by|Little Medicine Monster The latest generation of anti-HER-2 ADC drug developed by Hengrui, SHR-A1811, is often jokingly referred to as the domestic alternative to DS-8201 due to its similar structure. However, strength will eliminate all rumors. Results from early clinical studies released by AACR this year … Read more
With DS8201 continuously dominating the field of HER-2 solid tumors such as breast cancer, gastric cancer, and lung cancer, the pressure on other HER2-ADCs is increasing day by day. Faced with a suddenly strong competitor, various HER2-ADC manufacturers have their own responses; some choose to join forces when they cannot compete, quickly following in the … Read more
Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more